DNL.L Share News (DNL)

IP Group Swings To Loss In First-Half On Reduction In Portfolio Gains

LONDON (Alliance News) - IP Group PLC on Wednesday said it saw a swing to loss in the first half of 2018 despite an improvement in its portfolio valuation.The intellectual property-based to

Abcam Appoints Former Celltech CFO As Non-Executive Chairman

LONDON (Alliance News) - Life sciences company Abcam PLC said Monday it has appointed the former chief financial officer of Celtech Group PLC as a non-executive chairman.Peter Allen is a at

Diurnal To Raise GBP10.5 Million Via Share Placing (ALLISS)

LONDON (Alliance News) - Diurnal Group PLC said on Tuesday that it intends to raise GBP10.5 million through the placing of different types of shares.The

Diurnal Nets GBP500,000 From Broker Option Exercise (ALLISS)

LONDON (Alliance News) - Pharmaceutical firm Diurnal Group PLC on Tuesday said that it has received a letter of notice to exercise the broker option in respect of 263,157 in

UPDATE: Diurnal Prepares For First Revenue As Appoints Trial Partner

LONDON (Alliance News) - Pharmaceutical firm Diurnal Group PLC on Monday appointed a clinical trial services provider for its Chronocort treatment, as it posted a widened loss

Diurnal Interim Loss Widens On Cost Rise As Prepares For First Revenue

LONDON (Alliance News) - Pharmaceutical firm Diurnal Group PLC said Monday its interim loss widened amid a rise in research and administrative expenses, as it prepares to its

UK Stocks-Factors to watch on March 12

March 12 (Reuters) - Britain's FTSE 100 index is seen opening up 8 points higher at 7,233 on Monday, according to financial bookmakers. * GKN-MELROSE: GKN has struck a deal

Diurnal Agrees Two Deals With UDG Healthcare Ahead Of Infacort Launch

DIRECTOR DEALINGS: Diurnal Non-Executive Ups Interest

Director dealings: Diurnal trio dip in after EMA submission in December

(ShareCast News) - A trio of Diurnal Group directors bought shares in the hormone disease specialist, which remain little higher than the low reached late last year. Chairman Peter Allen bought 40,000 shares at 105p and non-executive directors Sam Williams and John Goddard bought 9,248 each at a pri

Diurnal Hires Outgoing Mereo BioPharma Finance Chief Bungay

Diurnal Submits European Marketing Application For Infacort

Diurnal Doses First Testosterone Replacement Therapy Trial Patients

UK Earnings, Trading Statements Calendar - Next 7 Days

Diurnal and IP Group eye 2017 launch for childhood hormonal treatment

(ShareCast News) - Diurnal Group, 45%-owned by university spin-out specialist IP Group, has produced positive clinical trial results for its treatment for a rare hormonal disease in young children. A European Phase III study for AIM-quoted Diurnal's Infacort treatment for paediatric Adrenal Insuffic